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Abstract
Background: Aspergillus flavus is intensively studied for its role in infecting crop plants and contaminating produce
with aflatoxin, but its role as a human pathogen is less well understood. In parts of the Middle East and India, A.
flavus surpasses A. fumigatus as a cause of invasive aspergillosis and is a significant cause of cutaneous, sinus, nasal
and nail infections.
Methods: A collection of 45 clinical and 10 environmental A. flavus isolates from Iran were analysed using
Variable-Number Tandem-Repeat (VNTR) markers with MICROSAT and goeBURST to determine their genetic diversity
and their relatedness to clinical and environmental A. flavus isolates from Australia. Phylogeny was assessed using
partial β-tubulin and calmodulin gene sequencing, and mating type was determined by PCR. Antifungal
susceptibility testing was performed on selected isolates using a reference microbroth dilution method.
Results: There was considerable diversity in the A. flavus collection, with no segregation on goeBURST networks
according to source or geographic location. Three Iranian isolates, two from sinus infections and one from a
paranasal infection grouped with Aspergillus minisclerotigenes, and all produced B and G aflatoxin. Phylogenic
analysis using partial β-tubulin and calmodulin sequencing confirmed two of these as A. minisclerotigenes, while
the third could not be differentiated from A. flavus and related species within Aspergillus section flavi. Based on
epidemiological cut-off values, the A. minisclerotigens and A. flavus isolates tested were susceptible to commonly
used antifungal drugs.
Conclusions: This is the first report of human infection due to A. minisclerotigenes, and it raises the possiblity that
other species within Aspergillus section flavi may also cause clinical disease. Clinical isolates of A. flavus from Iran are
not distinct from Australian isolates, indicating local environmental, climatic or host features, rather than fungal
features, govern the high incidence of A. flavus infection in this region. The results of this study have important
implications for biological control strategies that aim to reduce aflatoxin by the introduction of non-toxigenic
strains, as potentially any strain of A. flavus, and closely related species like A. minisclerotigenes, might be capable of
human infection.
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Background
Aspergillus flavus, notorious for its production of the
toxic and carcinogenic mycotoxin aflatoxin, is also cap-
able of affecting human health through infection and
pathogenic growth. While life-threatening disseminated
disease only occurs in people with relatively severe immu-
nocompromise, A. flavus can cause superficial infections
of the skin and nails, and localized infection within the
sinuses in otherwise healthy people. These infections are
particularly prevalent in warmer regions of the world, par-
ticularly the Middle East, where A. flavus is the dominant
pathogen in fungal sinusitis and keratitis [1].
Although encountered worldwide, the growth of A.
flavus is enriched by certain agricultural crops including
corn, peanuts, pistachio and cotton [2]. A. flavus is a ra-
pidly growing fungus, producing large numbers of mi-
croscopic asexual conidia that are readily dispersed and
are the infectious propagule. Population genetic ana-
lyses suggest that A. flavus has a largely panmictic po-
pulation structure [3,4], however there is also evidence
of clonally derived outbreaks associated with human
infection [5].
Iran has a largely agricultural economy and a warm
climate that favors the growth of thermotolerant fungi
like A. flavus, which has been isolated from certain crops
and associated soils [6]. A. flavus is the leading cause of
chronic fungal rhinosinusitis in Iran [7], and it has been
isolated from the air, internal surfaces and surrounding
soils of a number of Iranian hospitals [1]. Population
genetic studies of the hospital-related isolates using RAPD
analysis found these divided into two distinct groups,
however no standard strains were included and it was
not possible to compare these with other global iso-
lates. Denghan et al. [8] reported the cultural charac-
teristics and mycotoxin profiles of a set of 55 clinical
and environmental isolates from Iran belonging to the
A. flavus species complex. All but one of the clinical
isolates was A. flavus, relatively few (11.1%) were afla-
toxigenic, and one clinical isolate was A. oryzae [8].
The aim of the current study was to examine the gen-
etic diversity and population structure of the clinical A.
flavus isolates collected by Denghan et al. [8]. Multilocus
variable-number tandem repeat analysis (MLVA) was used
to compare these with type strains of A. flavus, A. para-
siticus, A, sojae and A. oryzae, and with a selection of
clinical and environmental isolates from Australia, in-
cluding one isolate of A. minisclerotigenes. We show here
that clinical Iranian isolates are diverse and related to their
environmental counterparts and to Australian isolates,
with one isolate indistinguishable from an isolate from
Australia. We report the first isolation of A. miniscleroti-
genes from Iran, and the first association of this species
with clinical disease, with isolates obtained from one para-
nasal and one sinus infection.
Material and methods
Isolates
Seventy isolates were included in an initial analysis of
the diversity of Iranian isolates. These included 45 clin-
ical A. flavus isolates, one clinical A. oryzae isolate and
10 non–clinical A. flavus isolates from Iran, along with 4
clinical and 2 non-clinical A. flavus isolates and one
non-clinical A. minisclerotigenes isolate from Australia.
Clinical isolates from Iranian patients were obtained du-
ring standard patient care at participating clinics, where
specimens and biopsies of the lesions were referred by
physicians to the Mycology Reference Laboratory in
School of Public Health, Tehran University of Medical
Sciences for diagnosis of the etiologic agents of in-
fection. For identification of fungal elements in tissues,
specimens were treated by potassium hydroxide (KOH)
and observed by direct microscopy. Portions of each spe-
cimen were inoculated on Sabouraud dextrose agar and
cultures were incubated at 25°C. Positive KOH prepa-
rations showed dichotomous septate branching hyphae in
tissue lesions. Identification of isolates as A. flavus was
confirmed by colony morphology on Czapeck agar media
and by microscopy following culture on malt extract agar
(MEA), as reported previously [8]. As isolations and diag-
noses were performed during routine clincial procedures
there was no requirement for ethical approval. Type
strains of A. flavus, A. parasiticus, A, sojae and A. oryzae
were also included in the isolate collection (Table 1).
As some of the Iranian isolates appeared similar to an
isolate that had previously been characterised as belong-
ing to A. flavus Group II (now formally described as A.
minisclerotigenes) [9,10] ten additional Group II-like iso-
lates from Australia, the USA and Africa were added to
the analysis [3]. Two additional type strains of A. oryzae
were also included, bringing the total number of isolates
to 80. All isolates along with their species name and ori-
gin are listed in Table 1.
Morphological identification of the Iranian isolates
was performed using standard methods of direct exa-
mination and culture, as described in Dehghan et al. [8].
Photomicrographs were produced using a Zeiss Axioscop
microscope fitted with Nomarski Interference Contrast
optics, a Zeiss Axiocam and Zeiss AxioVision software
(Carl Zeiss, Sydney).
Detection of aflatoxin production
Toxin production by isolates was assessed by inoculating
on coconut cream agar (50% coconut cream and 1.5%
agar) for 3 days at 30°C and observing colonies under long
wavelength (365 nm) ultraviolet light. Intense fluorescence
around the fungal colonies was presumptive evidence that
a strain could produce aflatoxin. Blue/violet fluorescence
indicated the production of B aflatoxin only, while a blue/
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VNTR allele size (bp) MLV
genotype
MAT
alleleAFPM1 AFPM4 AFPM5 AFPM6 AFPM7
Iranian clinical and non-clinical isolates
65822 A. flavus Iran Sinus Neg 122 205 215 345 256 1
65712 A. flavus Iran Sinus Neg 122 226 213 345 256 2
9573 A. flavus Iran Sputum Neg 122 219 215 345 193 3
2117 A. flavus Iran Nail Neg 122 217 215 345 250 5
1608 A. flavus Iran Nail Neg 122 195 215 345 248 7
65895 A. flavus Iran Neck Neg 122 220 215 345 193 8
2037 A. flavus Iran Nail Neg 122 213 213 345 239 9
65770 A. flavus Iran Sinus Neg 122 215 215 435 245 10
1097 A. flavus Iran Nail Neg null 220 215 345 248 11
65836 A. flavus Iran Sinus Neg 122 207 215 345 258 12
65811 A. flavus Iran Sinus Neg 122 220 215 345 300 13
65483 A. flavus Iran Sinus Neg 122 213 215 345 248 14
2141 A. flavus Iran Nail Neg 122 220 213 345 254 15




(B + trace G)
119 201 237 342 219 16 2
2165 A. flavus Iran Nail Neg 122 211 213 345 256 17
65938 A. flavus Iran Sinus Pos 122 207 215 345 254 18
65931 A. flavus Iran Sinus Neg 122 201 213 345 256 19
1698 A. flavus Iran Nail Neg 122 209 213 345 245 20
66246 A. flavus Iran Paranasal Neg 122 228 215 347 263 21
66204 A. oryzae Iran Sinus Neg 122 203 213 345 256 22
65760 A. flavus Iran Sinus Neg 122 219 213 null 254 23
65838 A. flavus Iran Lung (ball) Neg 122 197 213 345 241 24
292 A. flavus Iran Nail Neg 122 211 215 345 256 25
2666 A. flavus Iran Nail Neg 122 215 215 345 254 26
65817 A. flavus Iran Sinus Pos 122 215 215 345 256 27
65728 A. flavus (?) Iran Sinus Pos
(B + trace G)
123 197 211 348 null 28 1
4521 A. flavus Iran Nail Neg 122 215 215 345 248 29
2328 A. flavus Iran Nail Neg 122 222 215 347 252 30
65805 A. flavus Iran Sinus Neg 122 205 215 345 256 1
489 A. flavus Iran Nail Neg 122 215 215 345 248 29
66262 A. flavus Iran Sinus Neg 122 211 213 345 193 31
66086 A. flavus Iran Paranasal Neg 122 203 213 349 246 32
66161 A. flavus
(A. minisclerotigenes)
Iran Sinus Pos (B + G) 119 201 235 346 219 33 1
66150 A. flavus Iran Paranasal Neg 122 205 213 345 193 34
66666 A. flavus Iran Endocard Neg 122 195 213 345 256 35
1750 A. flavus Iran Nail Neg 122 199 213 345 253 37
66137 A. flavus Iran Paranasal Neg 122 209 213 345 245 20
65718 A. flavus Iran Sinus Neg 122 225 213 346 256 38
64726 A. flavus Iran Sinus Neg 122 215 215 345 248 29
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Table 1 Isolates included in study with VNTR alleles (Continued)
64729 A. flavus Iran Sputum Neg 122 195 215 345 248 7
65932 A. flavus Iran Sinus Neg 122 195 215 345 252 39
65717(1) A. flavus Iran Sinus Neg 122 213 213 345 193 40
65717(2)2 A. flavus Iran Sinus Neg 122 213 213 345 193 40
ES1 A. flavus Iran Pistachio Neg 122 215 215 345 248 29
ES2 A. flavus Iran Pistachio Neg 122 215 215 345 264 41
65841 A. flavus Iran Paranasal Neg 122 218 215 345 256 44
65848 A. flavus Iran Sputum Neg 122 217 213 345 241 45
TR A. flavus Iran Soil Pos 122 205 215 347 null 42
NTR A. flavus Iran Soil Neg 122 219 215 345 null 43
65806 A. flavus Iran Environment Neg 122 219 215 345 193 3
65824 A. flavus Iran Environment Neg 122 205 215 345 256 1
65773 A. flavus Iran Environment Neg 122 219 213 347 249 46
66130 A. flavus Iran Environment Neg 122 205 213 345 193 34
65844 A. flavus Iran Environment Neg 122 228 213 345 256 47
4941 A. flavus Iran Environment Neg 122 195 215 345 193 48
Australian clinical and non-clinical isolates
A5 A. flavus Australia Paranasal Neg 122 199 213 null 239 49
C3 A. flavus Australia Ear Neg 122 197 213 345 241 24
E3 A. flavus Australia Sputum Neg 122 188 213 345 252 53
E4 A. flavus Australia Sputum Neg 122 207 215 345 260 54
FRR 53053 A. flavus Australia Soil Pos 122 196 215 344 243 50
FRR 5309 A. minisclerotigenes Australia Soil Neg 119 186 271 342 219 51 1
FRR 5314 A. flavus Australia Soil Neg 122 188 213 344 249 52
Type strains3
NCPF 2008 A. flavus Unknown Ear Neg 122 203 213 345 239 4 1 + 2
PTCC 5006 A. flavus (A. tamarii) Iran Neg 122 159 213 343 221 61 1
JCM 2061 A. flavus Japan Neg 122 215 213 345 244 6 1 + 2
IMI 126842 A. oryzae USA Chinese soy
sauce
Neg 122 189 215 345 275 65 2
ATCC 15517 A. parasiticus Japan Pos 116 181 244 350 241 63
NRRL 255 A. parasiticus USA Soil Pos 116 181 245 350 235 62 1
IMI 191303 A. sojae Japan Neg 116 181 230 363 231 64
A. flavus "Group II" isolates4
FRR 2755 A. flavus
(A. minisclerotigenes)
Australia Peanuts Neg 119 196 287 342 219 55
FRR 4472 A. flavus
(A. minisclerotigenes)
Australia Environment Pos (B + G) 119 186 341 342 219 60 1
FRR 4086 A. flavus
(A. minisclerotigenes)
Australia Environment Neg 119 186 271 342 219 66 1
LA2-5 SB A. flavus (?) USA Soil Pos (B) 119 184 215 348 235 56 1
MS22-41 SB A. flavus (?) USA Soil? Pos (B) 119 186 217 348 271 57
FRR 3384 A. flavus
(A. minisclerotigenes)
Africa Sunflower seeds 119 188 319 344 219 58 2
FRR 3382 A. flavus
(A. minisclerotigenes)
Africa Sunflower seeds 119 186 282 342 217 59
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white fluorescence indicated production of both B and G
aflatoxins [11].
Toxin production by strains with Aspergillus minis-
clerotigenes-like MLV profiles was further assessed using
LC-MS. Following growth of cultures overnight in coco-
nut cream broth (50% coconut cream in deionised water),
10 mL of the culture supernatant was removed and cen-
trifuged at 10,000 rpm for 10 min. A 5 mL aliquot of the
resulting supernatant was subjected to solid phase ex-
traction using a C-18 cartridge (900 mg, 4 mL reservoir,
Alltech, Australia) under vacuum. Elution was achieved
using 5 mL 100% acetonitrile. The eluants were reduced
to 200–300 μL and were then re-constituted to 1 mL with
20% acetonitrile. LC-MS/MS analysis was conducted on a
Quantum triple stage quadrapole (TSQ) mass spect-
rometer (Thermo Fisher Scientific, Waltham, MA, USA),
equipped with a quaternary solvent delivery system, a col-
umn oven, a photo-diode array detector and an auto-
sampler. A 20 μL aliquot of each sample was injected and
separated on a Hydro Synergi C18 analytical column
(150 mm × 2.0 mm, 5 μm particle size, Phenomenex,
NSW, Australia) at 30ºC. The following solvents with a
flow rate of 200 μL/min were used: A, 0.2% formic acid in
purified water; and B, 0.2% formic acid in acetonitrile. The
elution profile was a linear gradient for solvent B of 20%
to 100% in solvent A over 18 minutes. Ions were gener-
ated using an electrospray source in the positive mode
under conditions optimised for aflatoxin B1. Ions were ac-
quired in the selected reaction monitoring mode for each
aflatoxin as: B1 » 313 (241,285); B2 » 315 (259,287); G1 »
329 (200,243); G2 » 331 (313, 245). Quantification was
achieved using external calibration curves.
Extraction of DNA
DNA extraction was performed on samples grown on
CYA medium for 5 days at 30°C, and was based on the
method of [12]. Approximately 0.5 g of mycelia was
scraped from the surface of the fungal colony and col-
lected into a 1.5 ml microcentrifuge tube. Tubes con-
taining mycelia were immediately frozen with liquid
nitrogen, and the mycelia were ground to a fine powder
with a small plastic pestle (VWR Scientific) and then re-
suspended in 400 μl lysis buffer (50 mм Tris–HCl, 100
mм NaCl, 5 mм EDTA, 1% SDS). Five microlitres of
proteinase K (20 mg ml−1) was added, and the mixture
was incubated at 60°C for 30 min and then incubated
at 40°C for 2 h. Following incubation, 112 μl of 5 M
NaCl and 1/10 vol. CTAB (Cetyl Tri-methyl Amonium
Bromide) were added to the tube with incubation at
65°C for 10 min. An equal volume of chloroform isoa-
myl alcohol (24:1) was then added and tubes were left
on ice for 30 min. The mixture was centrifuged at
12,000 g for 10 min and the supernatant was transferred
to another tube, mixed with 200 μl of 3 M sodium ace-
tate (pH 5.2) and incubated overnight on ice. The fol-
lowing day, tubes were centrifuged at 2,000 g for 10 min
at 4°C, the supernatant was transferred to a new tube,
0.55 vol. isopropanol was added and DNA was precipi-
tated by centrifugation at 12,000 g at 4°C for 5 min. The
DNA pellet was washed by cold ethanol, dried and
resuspended in 50 μl TE buffer containing 10 μg/ml
RNase. DNA was electrophoresed in a 0.7% agarose
gel and visualized by ethidium bromide staining and
UV transillumination. Concentrations were standardized
to approximately 100 μg/mL by visual comparison with
known standards.
PCR amplification
VNTR markers AFPM1-7 were used to analyze the gen-
etic relatedness of isolates [13]. Difficulties were encoun-
tered in amplifying some of the strains using primers
AFPM2 and AFPM3, therefore only primers AFPM1
and AFPM4-7 were used (Table 2). Amplifications were
carried out as described in [13].
Phylogenetic and mating type analysis
Phylogenetic analysis of Iranian isolates grouping with A.
minisclerotigenes was done using partial β-tubulin and cal-
modulin gene sequences. Sequences were amplified from
selected isolates using MyTaq Red Master Mix (Bioline,
Table 1 Isolates included in study with VNTR alleles (Continued)




Environment Neg 119 186 303 342 219 67 1




Environment Pos (B + G) 119 186 319 342 219 68 1




Environment Pos (B + G) 119 186 267 342 219 69 1
1Molecular identification based on MLVA and on b-tubulin and calmodulin phylogeny; only listed if different to morphological identification.
2From same infection as 657 17(1).
3FRR: Food Research Laboratory, CSIRO (Australia); PTCC: Persian Type Culture Collection (Iran); JCM: Japanese Collection of Microorganisms; NCPF: National
Collection of Pathogenic Fungi (UK) IMI: International Mycological Institute (UK) ATCC: American Type Culture Collection (USA); NRRL: National Regional Reference
Laboratory (USA).
4VNTR data taken from [3] with 3 bp subtracted from each locus size to account for modified primers.
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UK) according to manufacturer’s instructions and pre-
viously published primers for β-tubulin (bt2a and bt2b,
[14]) and calmodulin (cf1 and cf4 [15]). Sequences were
edited in Geneious Pro 6.1.6 (created by Biomatters;
available at http://www.geneious.com/) and were aligned
with published Aspergillus section flavi sequences [10].
Phylogenetic analysis was undertaken using maximum
likelihood with the PAUP 4.0 plug-in for Geneious. 1000
replicates were used to determine bootstrap support
values. Accession numbers are provided in on the relevant
phylogenetic trees. All taxa information, matrices and
trees have been made available through TreeBASE
at the following URL: http://purl.org/phylo/treebase/
phylows/study/TB2:S15946.
Mating type analysis was performed on all Group II/A.
minisclerotigenes-like isolates in our collection along with
selected type strains. Mating type was determined by amp-
lification using MAT1-1 and MAT1-2 specific primers
(M1F and M1R, M2F and M2R; [16]) in separate reac-
tions. PCR amplification was performed using MyTaq Red
Master Mix (Bioline, UK) according to manufacturer’s
instructions.
Antifungal susceptibility testing
The susceptibility of A. minisclerotigenes isolates in our
collection was assessed for four antifungal agents that
are used to treat A. flavus infections: Itrconazole (ITZ),
voriconazole (VRZ), amphotericin B (AMB) and caspo-
fungin (CAS). Minimum inhibitory concentrations (MICs)
were determined using a modified version of the CLSI
microdilution protocol for filamentous fungi (M38-A2)
and yeasts (M27-A2) [17,18]. Drugs were diluted in 100%
DMSO (ITR and VOR) or sterile water (AMB and CAS)
to stock concentrations of 1,600 μg/mL. Two-fold serial
dilutions were made in RPMI-1640 medium across flat-
bottom 96 well microtitre plates to give drug concentra-
tions ranging from 0.015 – 8 μg/mL. Drug free and cell
free controls were included.
MIC reference strains A. flavus ATCC 204304 and As-
pergillus fumigatus ATCC 204305 were purchased from
the American Type Culture Collection. All Aspergillus
strains were grown on sabouraud dextrose agar (SDA)
and were incubated at 37°C for 5 – 7 days to obtain
good sporulation. Spores were collected by flooding agar
plates with 5 mL of sterile water containing 0.1% tween
20 and were counted with a haemocytometer and ad-
justed to 2 – 5 × 105 spores/mL. Suspensions were di-
luted 1:50, and 100 μL was added to 100 μL of diluted
drug in each well of the microtitre plate, giving a final
spore concentration of 2 – 5 × 103 spores/mL. Candida
krusei ATCC 6258 was included as an additional MIC
control. Following growth on SDA at 30°C for 48 hr, sin-
gle colonies of C. krusei were suspended in sterile water
and adjusted to a concentration of 1 – 5 × 106 cells/mL.
Microtitre plates were prepared as above and inoculated
with 100 μL of a 1:1,000 dilution of the working suspen-
sion, giving a final cell concentration of 0.5 – 2.5 × 103
cells/mL.
All plates were incubated for 48 hr at 37°C. Following
the CLSI protocol, Aspergillus MICs for ITR, VOR and
AMB were read as the drug concentration causing 100%
growth inhibition compared to the drug free control.
For CAS, the minimum effective concentration (MEC)
was the first drug concentration to inhibit normal hy-
phal development. For C. krusei, inhibition was read at
100% for AMB and at 80% for the remaining drugs. All
MIC testing was performed in triplicate on separate
days.
Data analysis
Analysis of genetic diversity
Simpson’s Index of Diversity was used to evaluate the
discriminatory power of each VNTR locus and for the
combination of the five loci for the Iranian and Australian
isolates. This was calculated using the formula:
1 −
1
n n − 1ð ÞÞ
XS
j ¼ 1
xj xj − 1
  ð1Þ
where n is the total number of isolates tested, S the
number of different genotypes and xj is the number of
isolates belonging to the jth genotype [19]. The index
was calculated using the Discriminatory Power Cal-
culator available at http://insilico.ehu.es/mini_tools/
discriminatory_power/.
The probability of a genotype occurring more than




x! G−xð Þ! Pð Þ
x 1 − Pð ÞG−x ð2Þ
where G is the number of genotyped isolates in the popu-
lation, P is the probability of the observation of the geno-
type in question (which is the product of the frequency of
each allele found at a locus) and n is the number of
isolates with the same genotype as that in question. In the








AFPM-1 (CCA)n(CTA)n(CCA)n 3 0.1205
AFPM-4 (CA)n 21 0.9406
AFPM-5 (AG)nAC(AG)n 5 0.5506
AFPM-6 (GT)n 8 0.3682
AFPM-7 (AC)n 20 0.9064
All loci 53 0.9913
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case of pairs of identical genotypes, n = 1 and the formula
reduces to
Pse ¼ 1 – 1 – Pð ÞG [20].
Analysis of genetic structure
Initial analysis of the MLV data used MICROSAT ver-
sion 1.4 to calculate pairwise population distances using
the proportional shared allele distance measure (DPs)
[21]. Null alleles were scored as missing data. Pairwise
distances were used to construct dendrograms using the
Neighbour-Joining algorithm [22] available in the pro-
gram PHYLIP 3.5c Bootstrap analyses were performed
in MICROSAT with 1,000 replications. A. parasiticus re-
ference strains were used as the outgroup.
To further analyze the structure of the Iranian po-
pulation and to integrate this with other isolates a
network-based approach was used using goeBURST with
Minimum Spanning Tree implemented in PHYLOVIZ 1.0
[23] (available at http://goeburst.phyloviz.net/#Software).
Isolates were assigned multilocus variable-number tandem-
repeat (MLV) genotypes based on their VNTR data
(Table 1) and these were integrated with taxonomic,
geographic, clinical and toxin data to visualize and
assess the relationships among strains.
Results
Iranian clinical isolates are diverse with some clonally
related groups
VNTR loci AFPM-1, −4, −5, −6 and −7 were successfully
amplified from the strains included in the initial analysis
of Iranian and Australian isolates, yielding single bands
in the expected size range (Table 1). Occasionally a VNTR
locus could not be amplified from an isolate, and these
were scored as null alleles and treated as missing data. Dif-
ficulties were encountered amplifying loci AFPM-2 and
AFPM-3, which gave poor or no amplification or extra,
spurious bands. Since this occurred with DNA from
Australian isolates that had previously amplified with
the primers specific to these loci [3] it was assumed
that this was not due to genomic differences in this group
of isolates, but that there were problems with primer deg-
radation or sensitivity. As sufficient diversity was seen
with the remaining five VNTR loci (Table 2), AFPM 2 and
AFPM-3 were omitted from further analysis. The VNTR
markers revealed a high degree of diversity among the
Iranian isolates. Forty-eight unique multilocus variable-
number tandem-repeat (MLV) genotypes were observed
among the 58 isolates. Simpson’s Index of Diversity for
the combined MLV was 0.9913 (Table 2).
Neighbour joining (NJ) and parsimony analyses con-
ducted on the MLV dataset were used to construct pre-
liminary dendrograms of strain relatedness. Dendrogram
structure was largely congruent, and the NJ dendrogram
is shown in Figure 1A. Considerable diversity is apparent
among the Iranian isolates, and there is no obvious par-
titioning according to source (clinical or environmental)
or type of infection. A number of clonally related groups
containing isolates with identical MLV genotypes are
apparent. Four of these groups include both clinical and
environmental Iranian isolates, and one clonal group
consists of an Iranian clinical isolate (65838) and an
Australian clinical isolate (C3). Based on the frequency
of the alleles that the clonally related isolates groups
share (equation 2, above), all but two isolate pairs (Iranian
isolates 9573 & 65806, and 66150 & 65130) were un-
likely to appear to be clonally related by chance (p < 0.05;
Table 3), and it therefore appears that these groups con-
tain genetically identical isolates.
Some Iranian clinical isolates group with A.
minisclerotigenes
Two Iranian clinical isolates (66161 and 66041) grouped
on the dendrogram with isolate FRR 5309, which has been
characterized as A. minisclerotigenes [10], and one isolate
(65728) lay outside the entire A. flavus group. To deter-
mine the relationship of these isolates with A. miniscleroti-
genes, ten isolates that were previously categorized as A.
flavus Group II [3] and are likely to be A. minisclerotigenes
[10] were added to the analysis (Table 1).
Figure 1B shows the dendrogram drawn using the MLV
data for the Iranian collection with the addition of the A.
flavus Group II isolates. From this it was clear, first that
most isolates previously characterized as Group II lie in a
monophyletic cluster that contains A. minisclerotigenes
isolate FRR 5309; and second, that the Iranian clinical iso-
lates 66161 and 66041 fit within this same cluster. Iranian
isolate 65728 lay on the outside of the A. minisclerotigenes
group. This isolate shares similar VNTR alleles with the
Group II isolates but has a 123 bp allele for AFPM-1 while
all other Group II isolates examined to date have a 119 bp
allele at this locus (Table 1; Tran-Dinh 2002) [3].
Microscopy and toxin analysis of A. minisclerotigenes-like
isolates 66161, 66041 and 65728
Microscopic analysis of isolates 66161, 66041 and 65728
revealed these to have metulae, phialids and smooth spores
indistinguishable from those of A. flavus (Additional file 1:
Figure S1). This is typical for A. minisclerotigenes, which is
only morphologically distinguished from A. flavus by the
production of small sclerotia [10].
A. minisclerotigenes isolates are known to produce
both B and G aflatoxins, unlike A. flavus which can only
make B aflatoxin. Bright blue-white fluorescence indica-
tive of B and G aflatoxin was produced by isolate 66161
when grown on CCA, while 65728 and 66041 produced
a moderate level of fluorescence. LC-MS was underta-
ken to confirm toxin analysis in these isolates (Table 4).
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66161 was confirmed as a robust aflatoxin producer.
Isolates 65728 and 66041 produced B and trace levels of
G aflatoxins. All of the toxin profiles were dominated
by aflatoxin B1.
Integration of MLV genotypes with isolate data using
goeBURST network analysis
goeBURST networks, drawn using the Minimum Span-
ning Tree expansion implemented in PHYLOVIZ [23] were
used to visually integrate the MLV genotypes (Table 1)
with taxonomy, clinical/environmental source and toxi-
genicity. Networks were initially drawn at single-, double-,
and triple-locus variant levels (Additional file 2: Figure S2).
All MLV genotypes were connected at the triple-locus
variant level (TLV; Additional file 2: Figure S2A). The
double-locus variant (DLV; Additional file 2: Figure S2B)
level resolved type strains of A. parasiticus and A. sojae
into a separate cluster and also separated the A. miniscler-
otigenes-like isolates, including Iranian clinical isolates
66041 (MLV genotype 16) and 66161 (MLV genotype 33),
into a distinct cluster. Iranian isolate 65728 (MLV geno-
type 28), which was outside the A. minisclerotigenes group
on the dendrogram (Figure 1B), did not group with other
A. minisclerotigenes-like isolates and separated from all










































































































































































Figure 1 Neighbor-joining phylograms of clinical and environmental Aspergillus flavus isolates based on MLV data. A) Iranian and
Australian isolates; B) Inclusion of additional Group II/A. minisclerotigenes isolates. Iranian clinical isolates 66401 and 66161 lie within the Group
II/A. minisclerotigenes group, while isolate 65728 lies on the outside of this group.
Table 3 Probability of isolates having identical MLV
genotypes
MLV group Isolates Pse
1 658221, 658291, 658051 & 658242 0.022
3 95731 & 658062 0.24
7 16081 & 647291 0.03
20 16981 & 661371 0.031
24 653831 & C33 0.046
29 45211, 4891, 647261, & ES12 0.0098




Table 4 Aflatoxin produced following liquid culture in
CCA (ng/mL)
Isolate B1 B2 G1 G2
66161 12 498.2 6 598.2 19.6 27.8
66041 1 614.7 161.1 0.4 0.9
65728 7 002.3 562.9 0.4 0.4
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level (Additional file 2: Figure S2C) resolved A. parasiticus
and A. sojae and separated A. tamarii from the remaining
A. flavus isolates.
As the resolution of closely related species groups oc-
curred at DLV level, with complete separation of species
at the SLV level, Figure 2 shows the network drawn at
the SLV level, with dotted lines connecting MLV geno-
types that were joined at the DLV level. On this network,
MLV genotypes are integrated with taxonomic (2a), geo-
graphic (2b), clinical/environmental source (2c) and
toxigenicity (2d) data. Taxonomy of the isolates is clearly
resolved, reinforcing the association of Iranian A. minis-
clerotigenes-like isolates 66041 and 66161 (white arrow-
heads) with the A. minisclerotigenes group; however on
the network it is apparent that isolate 65728 (black
arrowhead), which lay on the outside of the A. miniscler-
otigenes cluster on the dendrogram (Figure 1) is not
related to A. minisclerotigenes and may be different to
the other species included in the analysis.
There was no obvious clustering of isolates on the net-
work in relation to geographic origin (Figure 2B), source
(Figure 2C) or toxigenicity (Figure 2D). However, the two
USA Group II/A. minisclerotigenes-like isolates (LA-5
SB; MLVA genotype 56 and MS22-41SB; MLVA geno-
type 57) that are known to produce B aflatoxin only
separated from the rest of the A. minisclerotigenes-like
group at the SLV level (Figure 2D, Additional file 2:
Figure S2C).
Phylogeny confirms two clinical isolates from Iran are
A. minisclerotigenes
β-tubulin and calmodulin gene sequences were used
to confirm the phylogenetic relationship of Group II/
A. minisclerotigenes-like isolates with species within As-
pergillus section Flavi (Figure 3 and Additional file 3:
Figure S3). On both trees the majority of the Group II/A.
minisclerotigenes–like isolates, including Iranian clinical
isolates 66041 and 66161, formed a distinct cluster with
71% (calmodulin) and 95% (β-tubulin) bootstrap support
that contained characterized A. minisclerotigenes isolates
[10], including FRR5309. Iranian clinical isolate 65728
grouped away from this cluster with other close relatives
of A. flavus. Also notable on this tree, Iranian A. flavus
type strain PTCC5006 from the Persian Type Culture
Figure 2 goeBURST networks of clinical and environmental Aspergillus flavus isolates. Networks were drawn using the Minimum Spanning
Tree expansion implemented in PHYLOVIZ. Circles represent MLV genotypes and are proportional to the number of isolates with the same
genotype; MLV genotypes are numbered as shown in Table 1. Solid lines show genotypes joined at the double locus variant (DLV) level; dashed
lines show genotypes joined at the single locus variant (SLV) level. Networks are integrated with A) taxonomic; B) geographic; C) clinical; and D)
toxin data. White arrows: Iranian A. minisclerotigenes isolates 66041 and 66161; black arrow: Iranian isolate 65728.
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Collection grouped with A. tamarii and A. flavofurca-
tus. This was consistent with the morphology of this
isolate (Denghan, unpublished) and it appears that it
has either been misidentified or has been inadvert-
ently swapped with an A. flavus isolate. Group II-like iso-
late LA2-5 SB, which separated from other A.
minisclerotigenes-like isolates on the goeBURST network
at the SLV level (Figure 2; Additional file 2: Figure S2C)
also did not cluster with A. minisclerotigenes isolates in
the two phylogenies. Finally, isolate BN038-G SBG, which
is characteristic of “SBG” isolates from West Africa that
have yet to be classified [24], grouped with A. parviscler-
otigenes [25] on both phylogenies with high bootstrap
support.
Both mating types are present in A. minisclerotigenes
Recent studies have established that A. fumigatus and A.
flavus are sexual species with two mating types, MAT-1
and MAT-2, and primers have been developed to amplify
these loci from different Aspergillus species [16]. Am-
plification of the A. minisclerotigenes isolates in our col-
lection found both mating types to be present, although
the MAT-1 mating type dominated (Additional file 4:
Figure S4; Table 1). The two Iranian A. minisclerotigenes
isolates were of opposite mating type. Although not direct
evidence for sexual recombination, this indicates that re-
combination may be possible in the Iranian A. miniscle-
rotigenes population. Two of the A. flavus type culture
isolates, NCPF 2008 (from the National Collection of
Figure 3 Phylogenetic placement of Group II/A. minisclerotigenes-like isolates in Aspergillus section flavi. A 444 bp fragment of the
β-tubulin gene was amplified from Group II/A. minisclerotigenes-like isolates and aligned with published Aspergillus section flavi sequences from
[10], using A. leporis as an outgroup. Maximum likelihood trees were drawn using the PAUP 4.0 plug-in for Geneious R6.1.6; bootstrap support
was obtained using 1000 replicates. Isolates sequenced in this study are indicated by a dot at the terminus of their branch: white = strains from
culture collections; grey = Group II isolates from our collection; black = clinical Iranian isolates. Most of the Group II isolates from our collection
along with Iranian clinical isolates 66041 and 66161 form a distinct cluster with 95% bootstrap support with isolates previously characterized as
A. minisclerotigenes [10], including isolate FRR5309. Iranian clinical isolate 65728 groups away from this cluster with A. flavus and closely related
species. Group II-like isolates LA 2–5 SB and BN038 G SGB group within the A. flavus cluster and with A. parvisclerotigenes, respectively. Accession
numbers for sequences are listed after the name of the relevant isolate. *denotes FRR.
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Pathogenic Fungi, UK) and JCM 2061 (from the Japanese
Collection of Microorganisms) had both MAT-1 and
MAT-2 alleles, indicating diploidy or aneuploidy at this
locus and the possibility of homothallism. Iranian isolate
65728 and the six remaining A. minisclerotigenes isolates
had the MAT-1 allele.
Drug susceptibility of A. minisclerotigenes is similar to
that of A. flavus
Susceptibility testing using CLSI microbroth dilution
methods was performed on all A. minisclerotigenes iso-
lates in our collection and on five clinical and one en-
vironmental Iranian A. flavus isolates, with the results
shown in Table 5 (for complete dataset see Additional
file 5). Epidemiological cut-off values (ECVs) have been
established for the response of A. flavus populations to
antifungal drugs as AMB: 2; ITR: 1; VOR: 1 and CAS
(MEC): 0.06 [26-28]. All of the isolates tested had MIC
values equal to or less than the ECVs for each drug, in-
dicating that they do not have unusual drug susceptibil-
ities. There were no significant differences between the
MIC values for A. flavus and A. minisclerotigenes.
Discussion
A. flavus is a particularly important fungus in human
health, both through the production of highly toxic and
carcinogenic secondary metabolites and through infection
of immunocompromised and immunocompetent people.
There are more than 25 described species and varieties
within the Aspergillus section Flavi [7,10,29], but while all
of these can produce various toxic metabolites very few
cause human infection. A. flavus, as the second most com-
mon cause of invasive aspergillosis behind A. fumigatus,
and the cause of most superficial, cutaneous, ocular and
sinus Aspergillus infections, is by far the most medically
important species in this group [7]. A. oryzae, which is a
non-toxigenic morphological variant of A. flavus, causes
occasional disease, and there are single reports of clinical
infection caused by A. tamarii, Petromyces alliaceus, A.
qizutongi and A. beijingensis [7]. In this study we report
for the first time human infection caused by A. minisclero-
tigenes, a recently described species within Aspergillus sec-
tion Flavi and closely related to A. flavus [10]. With two
clinical isolates among a collection of 46, A. miniscleroti-
genes may be a previously unrecognized cause of aspergil-
losis in Iran.
A. minisclerotigenes was first described as “A. flavus
Group II” by Geiser et al. (1998) and formed a dis-
tinct clade within a collection of A. flavus isolates from
Australian peanut growing soils [9]. Subsequent analyses
found fungi in this group were capable of producing B
and G aflatoxins as well as cycolpiazoic acid (CPA), a che-
motype that distinguished them from A. flavus, which
produces B aflatoxins and CPA, and A. parasiticus, which
produces B and G aflatoxins but not CPA. These fungi
were also characterized by the production of small scle-
rotia, leading to their eventual formal description as A.
minisclerotigenes [10]. Like A. flavus, A. minisclerotigenes
produces copious readily aerosolized conidia (Additional
file 1: Figure S1), however, although it has been found
sympatrically with A. flavus at relatively high levels in
crops and soils from Australia, West Africa, Argentina,
Algeria and Portugal [29,30], it is rare or absent from simi-
lar soil types sampled in the United States, India and Asia,
and prior to this study it had never been reported from
East Africa or the Middle East [9,31-33]. This suggests
that dispersal in these two species is different or that A.
minisclerotigenes is regulated by local factors that act to
suppress or enhance its growth.
The current study identified a third clinical isolate
(65728) that was distinct from both A. flavus and A. mi-
nisclerotigenes on the goeBURST networks (MLV type
28; Figure 2) but could not be distinguished from A. fla-
vus and related species by β-tubulin and calmodulin gene
sequencing (Figure 3 and Additional file 3: Figure S3).
This isolate produced B and trace levels of G aflatoxin and
may be another, as yet undescribed species within Asper-
gillus section Flavi. Given its ability to cause disease it
would be interesting to know whether related isolates can
be obtained from the environment in Iran.
As clinical disease can be caused by A. miniscleroti-
genes it was important to determine how this species
responds to antifungal drugs used to treat Aspergillus in-
fections. We therefore tested all of the A. miniscleroti-
genes isolates in our collection, along with six clinical
and one environmental Iranian A. flavus isolates and
the MAT-1/MAT-2 clinical A. flavus isolate NCPF2008,
to four commonly used antifungals. Antifungal break-
points have yet to be established for A. flavus, but large
collections of wild-type isolates (defined as having no
acquired or mutational mechanisms of resistance) have
been used to determine epidemiological cut-off values
Table 5 Antifungal MIC values for A. flavus and A. minisclerotigenes
Species AMB (MIC; μg/mL) ITR (MIC; μg/mL) VRZ (MIC; μg/mL) CAS (MEC; μg/mL)
Geomean Range Geomean Range Geomean Range Mode Range
A. flavus (n = 8)1 0.26 0.06-1 0.13 0.03-0.25 0.49 0.25-1 0.015 <0.015-0.03
A. miniscleotingenes and Group II-like (n = 6)2 0.3 0.125-0.5 0.1 0.03-0.25 0.37 0.25-0.5 0.015 <0.015-0.03
1Includes 6 Iranian and 2 clinical Australian isolates.
2Includes Iranian isolates 66041, 66161 and 65728.
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(ECVs) for AMB [26], CAS [28] and the triazoles [27],
which can be used to identify isolates with unusual drug
susceptibility. All of the A. minisclerotigenes isolates were
below the ECVs for each of the tested antifungals. Like-
wise the clinical and environmental Iranian A. flavus iso-
lates had MICs below the established ECVs and appear to
be similar in susceptibility to global A. flavus isolates. It
therefore appears that the antifungal regimes that are cur-
rently used for A. flavus are applicable to A. minisclero-
tigenes and to A. flavus infections in Iran, and it is not
necessary to differentiate between these two species in
order to treat clinical disease.
In the Middle East and India, A. flavus is not only the
leading cause of superficial aspergillosis but it can also
surpass A. fumigatus as the cause of invasive disease [34].
Exactly why Iran and other countries in the Middle East
have a much higher incidence of disease due to A. flavus
than is seen in other regions is not fully understood. Gen-
erally it is assumed that the hot and dry local climate fa-
vours growth of desiccation- and thermo-tolerant species
including A. flavus, and their higher environmental pres-
ence translates into a higher likelihood of infection [35].
However, parts of Australia have similar climatic condi-
tions, and a recent survey found Australian peanut grow-
ing soils to be exceptionally high in A. flavus propagules,
with a mean of >5,000 (SD > 20,000) CFU/g [33], yet A.
flavus is a rare cause of infection in Australia. In the cur-
rent study we hypothesized that fungal factors might un-
derlie these differences and therefore that Iranian clinical
isolates might be genetically distinct from their environ-
mental counterparts, and from clinical and environmental
isolates from Australia. goeBURST analysis of VNTR loci
was unable to detect any differentiation among these
groups, however, and in fact some genetically identical iso-
lates were found across these groups (Figure 2; Table 3).
This is in agreement with other studies that have found A.
flavus to have a globally panmictic population structure
[3,4,36], although at very local scales, such as single hospi-
tals or farms, single clades can dominate [5,36]. It is a
limitation of our study that we did not include more
Australian or global isolates, as we had initially assumed
we would be able to combine this analysis with a global
analysis already performed by Tran-Dinh (2002) [3].
Unfortunately, differences were noted in how bands were
sized following a change in equipment at the SUPAMAC
facility and it was not possible to combine datasets. This
problem has been noted by other researchers and is
an issue for establishing on-line accessible databases
for sharing MLV data [37]. Nonetheless, from our data it
seems reasonable to conclude that clinical A. flavus
isolates from Iran are not notably distinct from envi-
ronmental or Australian strains.
There was likewise no discernible differentiation
between toxigenic and non-toxigenic isolates, although
it was noted that in this collection there is a paucity of
toxigenic isolates, with only five for the 54 (9.25%) clin-
ical and environmental isolates testing positive for afla-
toxin. This is very similar to a recent study of A. flavus
from Iranian hospital environments, in which ~10% were
aflatoxigenic [1], and contrasts with findings from other
studies, where 20 - >90% of isolates from Australia, Asia
and the Americas have been found to be aflatoxigenic
[3,31,33,38]. It also differs to surveys of A. flavus from
corn and peanut-growing soils in Iran, in which 27.5% and
85% of isolates, respectively, produced B aflatoxins [6,39].
Different laboratory growth and assay conditions can in-
fluence the extent of toxin formation, however studies
from our laboratory have used the same toxin assays but
found other populations to contain more toxigenic isolates
[3,31], which suggests the level of aflatoxigenic isolates in
this clinical collection may be genuinely lower than in
most regions and in Iranian soils. Interestingly, TLC ana-
lysis of toxin production by isolates in this collection
by Denghan et al. [8] found isolates 66041 and 66161
(designated isolates 20 and 40, respectively, in their paper
and here identified as A. minisclerotigenes), produced the
highest levels of B aflatoxin. Further analysis of Iranian
crops and soil are needed to determine if A. miniscleroti-
genes is a significant source of aflatoxin contamination in
Iranian foodstuffs.
The study of Aspergillus taxonomy and the role of
aflatoxigenic species in clinical disease have important
implications for biocontrol strategies that aim to control
aflatoxin contamination of crops. These strategies rely
on competitive exclusion using non-aflatoxigenic strains,
which are seeded into fields to prevent colonization and
growth of native toxigenic strains [40-42]. While these
have shown promise in reducing aflatoxin levels in the
short term, the current study and others that have exa-
mined the diversity of clinical A. flavus isolates indicate
that potentially any A. flavus strain could cause infec-
tion in people and animals, and this could include non-
aflatoxigenic biocontrol strains. The use of a closely
related non-pathogenic species might reduce this risk,
but it is possible that like A. minisclerotigenes, other
close relatives of A. flavus can cause infection. There
is currently very little known about what determines
mammalian virulence in A. flavus [35]. Clearly these stu-
dies are essential before the safety of biocontrol strains
can be assured.
Conclusion
We report that clinical A. flavus isolates from Iran are not
significantly different from environmental or Australian
isolates, and that local geographic, climatic or host factors
are more likely than fungal factors to govern the relatively
high incidence of disease in this region. We report for
the first time that A. minisclerotigenes can cause human
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infection and that this species may also be an important
cause of aflatoxin contamination. Treatment of A. minis-
clerotigenes infection can be undertaken using the same
antifungal regime recommended for A. flavus. The pos-
sibility of clinical infection must be taken into account
when choosing A. flavus strains and related species for
control of aflatoxin in crops.
Additional files
Additional file 1: Figure S1. Light microscopy of conidial heads and
conidia from Iranian A. minisclerotigenes/Group II-like isolates. A) Strain
66041; B) Strain 66166; C) Strain 65728.
Additional file 2: Figure S2. goeBURST networks of clinical and
environmental A. flavus isolates. Networks are drawn at the A) triple-;
B) double-; and C) and single- locus variant levels. MLV genotypes
are as shown in Table 1. Separation of different Aspergillus species
occurs at the double- and single-locus variant levels.
Additional file 3: Figure S3. Phylogenetic placement of A.
minisclerotigenes-like isolates using partial sequence of the calmodulin
gene. Maximum likelihood trees were drawn using the PAUP 4.0
plug-in for Geneious R6.1.6; bootstrap support was obtained using
1000 replicates. Isolates sequenced in this study are indicated by a
dot at the terminus of their branch: white = strains from culture
collections; grey = Group II isolates from our collection; black = clinical
Iranian isolates. Most Group II isolates and Iranian clinical isolates
66041 and 66161 form a cluster with isolates previously characterized
as A. minisclerotigenes. Iranian clinical isolate 65728 groups with A.
flavus and other closely related species. Accession numbers for
sequences are listed after the name of the relevant isolate.
*denotes FRR.
Additional file 4: Figure S4. PCR amplification of mating type loci from
A. minisclerotigenes and selected type strains. Top panel: Amplification
with MAT-1 primers; bottom panel: Amplification with MAT-2 primers.
Lanes: 1. NCPF2008; 2. JCM2061; 3. PTCC 5006; 4. NRRL 255; 5. IMI
126842; 6. FRR5309; 7. 66041; 8. 65728; 9. 66161; 10.FRR 4472; 11.
FRR4086; 12. LA2-5 SB; 13. FRR 3384; 14. M40 N°1; 15. MEA511; 16;
MEA 342; 17. –ve control.
Additional file 5: Table S1. MIC data for Aspergillus minisclerotigenes
and selected A. flavus isolates.
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